Trials / Completed
CompletedNCT00878293
Painful Diabetic Polyneuropathy Trial With a New Centrally Acting Analgesic
A Randomized Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Pain Due to Diabetic Polyneuropathy
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 90 (actual)
- Sponsor
- Tris Pharma, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this trial is to determine whether the new centrally active analgesic and MS Continus® are effective in the treatment of painful diabetic polyneuropathy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GRT6005 | liquid formulation for oral application, 0,8 to 400 µg, single dose per day, five days |
| DRUG | MS Continus® | 60 mg, capsule, once daily |
| DRUG | Placebo | liquid formulation and capsule, once daily |
Timeline
- Start date
- 2009-04-01
- Primary completion
- 2010-05-01
- Completion
- 2010-05-01
- First posted
- 2009-04-08
- Last updated
- 2021-07-15
Locations
4 sites across 2 countries: Germany, United Kingdom
Source: ClinicalTrials.gov record NCT00878293. Inclusion in this directory is not an endorsement.